The Sinopharm COVID-19 vaccine has an efficacy rate of nearly 80% within international standards, which means that —in general— it is a useful and safe product for the population, affirmed Eduardo Ticona, Chief of the Clinical Trials Unit at San Marcos University.
Ticona —who is responsible for Sinopharm's clinical trials in volunteers at San Marcos— emphasized that the vaccines must have an efficacy of 65% to be placed on the market and warned that none are 100% effective.
"If efficacy rates range between 80% and 90%, they are very good and useful for the population," he expressed.
"We are working blindly. We do not know which events are attributable to the vaccine or to the placebo," the doctor stated.
"However, we have noticed pain in the vaccination area, headaches, joint and muscle pain, fatigue, or numbness. We are awaiting efficacy results," he added.
Ticona explained that such adverse effects are similar to those seen in volunteers who received Pfizer and Moderna vaccines.
"People always experience discomfort when they receive vaccines. The important thing is that it is effective and safe. In fact, now we can see that. There seems to be no major problem," he concluded.
(END) RRC/RMB/MVB
Published: 1/7/2021